(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to ...
Mar 27, 2018
0
4
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers ...
Dec 19, 2017
0
7
UT Southwestern Medical Center researchers have developed a method to map protein changes that occur in different subtypes of breast cancer cells in response to DNA damage from a new class of chemotherapy drugs.
Nov 29, 2017
0
9
Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports.
Sep 5, 2017
0
4
Inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) kill BRCA-deficient tumours, and have significant activity in single agent and combination therapy. Professor Herbie Newell, of Newcastle University ...
Jul 25, 2017
0
21
In the summer of 2013, mum of two, Suzanne Harford went to see the doctor after noticing unusual changes in her monthly cycle. Thinking that she might have a common non-cancerous growth called a fibroid, her GP referred her ...
Jul 24, 2015
0
73
Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib.
Nov 20, 2014
0
0
Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, UCLA researchers have shown for the first time.
Nov 12, 2013
0
0
A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center ...
Oct 9, 2012
0
0
Olaparib (Lynparza), a targeted cancer drug, has been approved for hundreds of patients with certain breast cancers and prostate cancers in England.
Apr 11, 2023
0
22
